The intersection of AI with biotech research advances therapeutic targeting and drug discovery. Nobel laureate David Baker's lab developed AI models to design binders for intrinsically disordered proteins, unlocking difficult-to-drug targets implicated in diseases like cancer and diabetes. Chemify launched a fully automated facility integrating AI, chemistry, and robotics to accelerate molecular drug discovery. New analytics platforms and bioinformatics tools are emerging to better study protein phase separation and microbial identification, crucial for precision medicine and infectious disease diagnostics.